<?xml version="1.0" encoding="UTF-8"?>
<ack id="S18">
 <title>ACKNOWLEDGMENTS</title>
 <p id="P40">
  <italic>Financial disclosure:</italic> This study was funded by Celgene Corporation, Summit, NJ. The authors received editorial support during manuscript development from Sheila Truten and Kelly Dittmore of Medical Communication Company, Inc. (Wynnewood, PA) who were funded by Celgene Corporation. Analyses were performed by Celgene Corporation. The authors are fully responsible for all content and editorial decisions and had access to all study data.
 </p>
 <p id="P41">
  <italic>Conflict of interest statement:</italic> M.d.L.: Celgene Corporation, consultancy, research funding; Pfizer, board of directors or advisory committees; Incyte, consultancy; Amgen, consultancy; Spectrum, consultancy. B.O.: Celgene Corporation, AROG, and Astex, research funding. E.B.P.: spouse has leadership roles and stock ownership at Exelixis, Regulus, and Biogen. S.A.G.: Amgen, Celgene Corporation, Jazz Pharmaceuticals, Kite Pharma, Novartis, and Sanofi, consultancy; Spectrum, consultancy, research funding. B.L.S.: Celgene Corporation, honoraria, consultancy, research funding, speakers bureau; Novartis, research funding, speakers bureau; Alexion, honoraria, speakers bureau; Incyte, honoraria, speakers bureau; Acceleron, data and safety monitoring board; Agios Pharmaceuticals, honoraria, consultancy. B.M.W.: Miragen, consultancy, honoraria. J.H., E.L., B.H., and B.S.S.: Celgene Corporation, employment, equity ownership. C.C.: Celgene Corporation, honoraria, research funding; Jazz Pharmaceuticals, Pfizer, and Janssen, honoraria.
 </p>
</ack>
